|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, vonicog alfa (Veyvondi®▼) can be made available within NHS Wales for on-demand treatment of non-surgical and surgical (elective and emergency) bleeding episodes in children aged up to 17 years with von Willebrand disease. Vonicog alfa (Veyvondi®▼) will be available as a second line treatment, given when desmopressin treatment with or without tranexamic acid is ineffective or not indicated.
The risks and benefits of the off-label use of vonicog alfa (Veyvondi®▼) for this indication should be clearly stated and discussed with the patient to allow informed consent.
Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
This advice will be reviewed after 12 months or earlier if new evidence becomes available.
|Medicine name||vonicog alfa (Veyvondi®)|
|Formulation||650 IU and 1300 IU powder and solvent for solution for injection|
On-demand treatment of non-surgical and surgical (elective and emergency) bleeding episodes in children aged up to 17 years with von Willebrand disease
|Company||Takeda UK Ltd|
|BNF chapter||Nutrition & blood|
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||07/11/2022|